Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
about
Molecular subgroups of medulloblastoma: the current consensusAdvances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumorsDISP3 promotes proliferation and delays differentiation of neural progenitor cellsIntegrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcomeEstablishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation.NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.Arhgap36-dependent activation of Gli transcription factors.Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastomaMolecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.Recurrent carotico-cavernous fistula after internal carotid artery ligation: a case with embolization of the fistula via contralateral internal carotid artery approachCritical role of zinc finger protein 521 in the control of growth, clonogenicity and tumorigenic potential of medulloblastoma cells.Neuroradiology and histopathology in two cases of adult medulloblastoma.Rapid diagnosis of medulloblastoma molecular subgroups.Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features.Multi-study integration of brain cancer transcriptomes reveals organ-level molecular signaturesWNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastomaMedulloblastoma: advances and challenges.Molecular subgroups of medulloblastoma.Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization.ASC deficiency suppresses proliferation and prevents medulloblastoma incidenceThe molecular classification of medulloblastoma: driving the next generation clinical trials.Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.An interferon response gene expression signature is activated in a subset of medulloblastomasFunctional genomics identifies drivers of medulloblastoma dissemination.Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variablesThe occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation.Molecular diagnostics in embryonal brain tumors.Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trialCTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants.Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkersMedulloblastoma comprises four distinct molecular variants.Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugsClinicopathological analysis of hepatocellular adenoma according to new bordeaux classification: report of eight korean cases.
P2860
Q24615271-814C8CF5-EB20-4FA7-8410-DBDD39EB1C59Q26866408-CDC5C51A-73B2-4427-9109-DFE53BD89ADEQ28116426-E1E7F8BA-E043-41BD-BD54-F5F64780882DQ28298987-F9089F3C-EA76-402B-9C34-25E5EFA4BDCBQ33572502-6FA7C2D3-3B05-4653-BEB1-7CE631BDA3D4Q33622402-9FBD013C-2F83-4561-9FA2-AF23B0F2EC61Q33974923-02D2FAE2-906F-4A35-A071-2B2D9A201173Q34002623-F3E6DBBB-B48A-4262-B65B-1338A4AD5B7EQ34053468-D6C23479-1EB7-4A5E-8D46-E194AC2C5076Q34109094-8E1B8AAA-DF87-4D5A-937A-D018CC439C7AQ34167499-462684CE-01CF-4F71-95AC-0A2998C2EBF4Q34296928-AA129768-3CE3-4AD6-A3EA-B3E5C8DFFCF2Q34361233-AC43F9F9-83D6-4E6C-B94C-4FC578D497B4Q34369671-69814C6B-AB8B-4C3E-84EA-02D370F7BA22Q34764793-7BA7C229-854D-4537-9702-ED43131BF6CBQ34866372-0F44C1DE-BFFA-4829-AA8A-06C0FEFD34ADQ34916522-B905A017-5063-4287-818A-A1AC1FA15436Q34979270-0EFC928F-8712-44CF-917C-3DDA9F8B82BEQ35002014-746F9D91-714A-48A6-BB90-9D796EDB1B2DQ35101347-016CD38B-6B8C-4796-BC8C-60E45DED5E6DQ35542572-EFAF1205-E82C-4FFB-85DD-4999FAE14530Q35611341-A8B5F987-32B8-49E6-ADE4-F7F02FCBF24DQ35696363-A8F185B2-9F36-469C-8DB0-40EB6F63A764Q35729391-4172A0BB-956B-47C6-AB70-866807829840Q35832266-8BF202EB-8C0C-4E80-9FA5-4EE2095EC4B5Q35904348-D8EF670E-A5F2-42F4-B6A2-F4B35DDB8F43Q35946293-68C4C2D9-D7EE-4F5A-A55A-3F5F150BA7D4Q35960250-4C41D171-8331-4694-916B-6266D6F4F8EBQ36199866-ACEA0B1B-6C03-4659-99D8-D82B784E6FBCQ36296016-ABBC9698-8BA6-473A-8138-3CACD2C3BC03Q36460209-F2B847D0-BF17-42F6-BAC1-D4E37E846C52Q36476670-BB9DAC07-7E5E-4250-A684-436F9836A4A9Q36536422-6D4C02E0-A2AA-4CD0-8028-58797D8F9B9AQ36619093-3D9E3114-4A43-41C7-A9B4-0D72E8C0347EQ36629427-9D3055B9-A09E-44E1-8C8E-19D718F2E564Q36644748-CF102EE1-412D-4355-B8AF-4254B0B2BAAEQ36873451-6CF18769-6A21-4917-8F43-5B17E954CE4AQ36920479-6E14BACA-BC51-4B66-A187-4E9B2852137CQ37018003-62542D86-7767-4685-9C9A-7F8D7CF95BEEQ37316703-73E90A3E-7716-4865-B9DF-FD2502EC4271
P2860
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Beta-catenin status in paediat ...... and clinical characteristics.
@en
Beta-catenin status in paediat ...... and clinical characteristics.
@nl
type
label
Beta-catenin status in paediat ...... and clinical characteristics.
@en
Beta-catenin status in paediat ...... and clinical characteristics.
@nl
prefLabel
Beta-catenin status in paediat ...... and clinical characteristics.
@en
Beta-catenin status in paediat ...... and clinical characteristics.
@nl
P2093
P2860
P50
P356
P1476
Beta-catenin status in paediat ...... and clinical characteristics.
@en
P2093
Arielle Lellouch-Tubiana
Christine Haberler
Danielle Bours
Elodie Manie
Francois Doz
Marie-Anne Raquin
Patricia Legoix
Sabrina Carpentier
Sarah Fattet
Severine Lair
P2860
P356
10.1002/PATH.2514
P577
2009-05-01T00:00:00Z